Serina <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures $5 Million Funding Tranche and Gains Regulatory Approvals to Launch Global Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Inc. (NYSE American: SER), a clinical-stage biotechnology company, announced it has received the first $5 million tranche under a financing agreement totaling up to $20 million. The funding, provided solely to Serina Therapeutics, will support the planned registrational trial of SER-252, an investigational treatment for advanced Parkinson's disease. The company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration and obtained Human Research Ethics Committee (HREC) approval in Australia. Serina remains on track to initiate its global clinical trial in the fourth quarter of 2025, with first patient dosing expected before year-end. Subsequent funding tranches are contingent upon the achievement of key development milestones, including trial patient enrollment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-25-000122), on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.